ABIONYX PHARMA SA (ABNX.PA) Stock Income Statement
EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.55M | 4.64M | 5.25M | 675.00K | 0.00 | |||
| Cost Of Goods | 3.71M | 4.02M | 4.62M | 416.00K | 0.00 | |||
| Gross Profit | 844.00K | 618.00K | 636.00K | 259.00K | 0.00 | |||
| Operating Expenses | 5.31M | 4.03M | 4.75M | 6.21M | 2.97M | |||
| Research and Development | 2.99M | 2.90M | 2.56M | 5.68M | 2.31M | |||
| Selling, General, and Administrative Expenses | 3.31M | 2.61M | 3.53M | 2.23M | 1.27M | |||
| Operating Income | -4.46M | -3.41M | -4.11M | -5.95M | -2.97M | |||
| Interest Income/Expense | 40.00K | 1.00K | -16.00K | -14.00K | 94.00K | |||
| Other Income/Expense | 44.00K | -107.00K | -81.00K | 144.00K | 988.00K | |||
| Income Before Taxes | -4.38M | -3.52M | -4.21M | -5.82M | -1.89M | |||
| Income Tax | 0.00 | 0.00 | N/A | 0.00 | 0.00 | |||
| Net Income | -4.38M | -3.52M | -4.21M | -5.82M | -1.89M | |||
| EBITDA | -4.33M | -3.26M | -3.97M | -5.83M | -2.95M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.13 | -0.12 | -0.15 | -0.23 | -0.08 | |||
| Statistics | ||||||||
| Gross Profit Margin | 18.55% | 13.32% | 12.11% | 38.37% | N/A | |||
| Profit Margin | -96.26% | -75.82% | -80.08% | -862.52% | N/A | |||
| Operating Profit Margin | -98.11% | -73.53% | -78.24% | -881.78% | N/A | |||
All data in EUR